



1fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hu, Fang and Wu, Bo

Serial No.: 10/766,307

Filed: 01/28/2004

Group:

For: Therapy for Primary and Metastatic Cancer

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on August 2, 2004.

M. ALFORD M. Alford

Signature

M. ALFORD

Typed or Printed name of person signing Certificate

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, which ever event occurs last 37 C.F.R. § 1.97(b).

Respectfully submitted,
JACKSON WALKER L.L.P.

T. Ling Chwang
T. Ling Chwang
Registration No. 33,590

August 2, 2004

Dated:

JACKSON WALKER L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/766,307
		Filing Date	01/28/2004
		First Named Inventor	Hu, Fang and Wu, Bo
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	SSBC-0001 (121300.00003)
(use as many sheets as necessary)			
Sheet	2	of	5 Sheets

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
					T ⁶

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of

the reign of the Emperor must precede the serial number of the patent document.⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/766,307		
		Filing Date	01/28/2004		
		First Named Inventor	Hu, Fang and Wu, Bo		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	5 Sheets	Attorney Docket Number	SSBC-0001 (121300.00003)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	5	ALEMANY et al. (2000) Replicative adenoviruses for cancer therapy. <i>Nature Biotechnology</i> 18:723-727		T ²
	6	ANDERSON (1998) Human gene therapy. <i>Nature</i> 392:25-30		
	7	BANCHEREAU et al. (2000) Immunobiology of dendritic cells. <i>Annu. Rev. Immunol.</i> 18:767-81		
	8	BARKER AND BERK (1987) Adenovirus proteins from E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. <i>Virology</i> 156:107-21		
	9	BISCHOFF et al. (1999) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. <i>Science</i> 274:373-6		
	10	BASU AND SRIVASTAVA (2000) Heat shock proteins: the fountainhead of innate and adaptive immune responses. <i>Cell Stress & Chaperones</i> 5:443-451		
	11	BERMUDES et al. (2002) Live bacteria as anticancer agents and tumor-selective protein delivery vectors. <i>Curr Opin Drug Discov Devel.</i> 5(2):194-9		
	12	FALK AND ISSELS (2001) Hyperthermia in oncology. <i>Int. J. Hyperthermia</i> 17:1-18		
	13	FONG AND ENGLEMAN (2000) Dendritic cells in cancer immunotherapy. <i>Annu. Rev. Immunol.</i> 18:245-273		
	14	GONG et al. (1997) Induction of anti-tumor activity by immunization with fusion of dendritic and carcinoma cells. <i>Nat. Med.</i> 3:558-561		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5 Sheets

Complete If Known

Application Number	10/766,307
Filing Date	01/28/2004
First Named Inventor	Hu, Fang and Wu, Bo
Group Art Unit	
Examiner Name	

Attorney Docket Number SSBC-0001 (121300.00003)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
15		HANAHAN AND WEINBERG (2000). The hallmark of cancer. Cell 100:57-70	
16		HAVIV et al.(2001) Heat shock and Heat shock protein 70i enhance the oncolytic effect of replicative Adenovirus. Cancer Research 61:8361-8365	
17		HAWKINS et al. (2002) Oncolytic biotherapy: a novel therapeutic platform. The Lancet Oncology 3:17-26	
18		HOBOHM (2001) Fever and cancer in perspective. Cancer Immunol Immunother.50: 391-396	
19		KIRN et al. (2001). Replication-selective virus therapy for cancer: Biological principle, risk management and future directions. Nature 7:781-787	
20		KUGLER et al. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell. Nat.Med.6:332-336	
21		LI (1984) Thermal biology and physiology in clinical hyperthermia: current status and further needs. Cancer Res. (Suppl.) 44(8):48865-48935	
22		LI AND MAK (1985) Induction of heat shock protein synthesis in murine tumors during the development of thermotolerance. Cancer Res. 45(8):3816-3824	
23		LI et al. (1995) Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int. J. Hyperthermia 11(4): 459-488	
24		LINDQUIST AND CRAIG (1988) The heat-shock proteins. Annu Rev Genet;22:631-77.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Substitute for form 1449A/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
<i>(use as many sheets as necessary)</i>					
Sheet	5			of	5 Sheets
				Attorney Docket Number	SSBC-0001 (121300.00003)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	25	NESTLE et al. 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat.Med.4:328-332	
	26	RIES AND KIRN (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. British Journal of cancer 86:5-11	
	27	SRIVASTAVA AND JAIKARIA (2001) Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol. Biol. 156:175-186	
	28	VAN RIJN et al.(2000) Heat shock responses by cells treated with azetidine-2-carboxylic acid. Int J Hyperthermia 16:305-318	
	29	WALLEN et al.(1997) Oxidants differentially regulate the heat shock response. Int J Hyperthermia 13:517-24	
	30	WELCH (1992) Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72(4):1063-81.	
	31	WISCHMEYER (2002) Glutamine and Heat Shock Protein expression. Nutrition 18:225-228	
	32	YING et al. (2001) Innovative cancer vaccine strategies based on the identification of tumor-associated antigen. BioDrugs 15:819-31	
	33	ZYLICZ et al.(2001) HSP70 interactions with the p53 tumor suppressor protein. EMBO Journal 20:4634-4638	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.